Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety

PURPOSE: Although pegylated liposomal doxorubicin (PLD) has been approved in combination with bortezomib for relapsed/refractory multiple myeloma (MM), the antitumor efficacy and tolerability of PLD in different regimens for patients with newly diagnosed MM (NDMM) have not been fully defined. METHOD...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Zhai, Yujia, Yuan, Dai, Ge, Xueling, Hu, Shunfeng, Li, Peipei, Fang, Xiaosheng, Li, Ying, Zhou, Xiangxiang, Wang, Xin
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8030239/
https://ncbi.nlm.nih.gov/pubmed/33842312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.597453
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares